ALSO NOTED: Integra buys IsoTis for $49.3M; MannKind searches for insulin drug partner; and much more...

> Device maker Integra LifeSciences is buying IsoTis for $49.3 million. Release

> MannKind told investors on Friday that it faced an uncertain delay in finding a partner for its inhalable insulin candidate, and investors responded Monday by taking a bite out of the developer's share price. Adding to the uncertainty surrounding the company, MannKind says it is delaying the release of its second-quarter report until Aug. 9 and that CFO Richard Anderson is retiring. The monumental failure of Pfizer's Exubera--an inhalable insulin drug--to find a market niche may be making potential partners particularly skittish. Report

> KineMed has raised $15 million and plans to use the money to advance its lead drug candidate into clinical trials. Release

> Bayer Thai and Schering (Bangkok) have merged. Report

> Isotechnika announced that the FDA has granted fast track designation for its lead drug, ISA247. Release

> Entelos has struck a deal with the FDA to create a computer model for drug-induced liver damage. Release

> Abraxis BioScience has won regulatory approval to sell Oxytocin Injection in a 30 ml vial. Release

> In 2006, Pharma racked up a multibillion-dollar marketing bill. FiercePharma

> PricewaterhouseCoopers has released a study based on interviews with 185 top pharma execs in the Asia-Pacific region. The verdict? Not only are China, India, Singapore and their neighbors poised to become huge pharmaceuticals consumers, but big producers as well. FiercePharma

And Finally… Drinking more than three cups of coffee a day may help women delay memory loss. Report